Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
What is a biosimilar
The future of biosimilars
Considerations for biologic switching
Inflectra/CT-P13* has robust clinical data for switching patients from Remicade®† to Inflectra/CT- P13*.1-10
EU and UK guidance supports switching from reference biologics to a biosimilar in appropriate patients.11-14
Decisions regarding treatment choice or physician-mediated switching must be a clinical decision made by a treating physician on an individual patient basis, supported by scientific evidence, ensuring safety of patients is not compromised, and with patient awareness.
*CT-P13 is marketed under different brand names including Inflectra and REMSIMA®.
†Remicade® is a registered trademark of MSD.
Learn about the dosing and administration of Inflectra in patients with rheumatoid arthritis
Find out more
Learn about the safety profile of Inflectra in patients with rheumatoid arthritis
Inflammatory bowel disease
Infliximab mechanism of action
Support & Resources
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020